Unnatural Products and Novartis Ink License Deal for Macrocyclic Peptide Cardiovascular Program
Unnatural Products has entered a licensing agreement with Novartis to advance macrocyclic peptide therapies targeting a cardiovascular program. The California-based company will receive an upfront payment and is eligible for substantial milestone payments and tiered royalties, while Novartis will manage clinical development, manufacturing and globa…